Maresin1通过TLR4/NF-κB/NLRP3通路抑制焦亡减轻下肢缺血再灌注损伤的机制

doi:10.3969/j.issn.1006-5725.2026.10.020

摘要/Abstract

摘要：

目的探讨Maresin1（MaR1）通过抑制细胞焦亡减轻下肢缺血再灌注损伤的作用机制。方法本研究采用体内外实验相结合。体内实验共使用27只C57BL/6小鼠随机分为对照组（Control组）、模型组（LL-IRI组）和治疗组（MaR1组）。造模成功并药物干预后，取各组5例（n = 5）小鼠腓肠肌组织进行转录组测序与生物信息学分析；其余样本用于评估组织病理损伤、检测toll样受体4（TLR4）/核因子-κB（NF-κB）p65及核苷酸结合寡聚化结构域样受体蛋白3（NLRP3）/Gasdermin-D（GSDMD）蛋白表达；试剂盒测定采集后的小鼠血清中MDA含量及CAT活性。体外实验采用LPS联合ATP刺激L6骨骼肌细胞构建焦亡模型，分组造模后行ELISA检测各组细胞上清IL-1β与IL-18含量。结果 BulkRNA测序分析提示，与对照组相比，LL-IRI组中TLR4/NF-κB/NLRP3信号通路以及细胞焦亡相关基因表达显著上调，经MaR1干预后可逆转以上趋势，并负向调控炎症小体活化与细胞焦亡相关生物学过程。组织病理切片显示LL-IRI 组肌纤维排列紊乱、断裂明显，免疫荧光佐证生信分析，TLR4/NF-κBp65与NLRP3/GSDMD的蛋白表达显著增强（P < 0.01），且伴随血清MDA含量升高（P < 0.01）、CAT活性下降（P < 0.01）。MaR1治疗能显著改善上述病理、分子及生化指标。体外实验结果表明LPS+ATP组较正常组相比，焦亡终末炎症因子IL-1β与IL-18的释放水平明显上升（P < 0.01），在MaR1干预后能有效抑制IL-1β与IL-18的释放（P < 0.01）。结论 MaR1可能通过阻断TLR4/NF-κB/NLRP3炎症级联抑制细胞焦亡，从而减轻小鼠下肢缺血再灌注损伤。

关键词: Maresin1, 下肢缺血再灌注损伤, 细胞焦亡, toll样受体4

Abstract:

Objective To investigate the mechanism by which Maresin1 reduces lower limb ischemia-reperfusion injury through the inhibition of pyroptosis. Methods This study employed a combination of in vivo and in vitro experiments. In the in vivo experiment， 27 C57BL/6 mice were randomly allocated into the Control group， the model group （LL-IRI）， and the treatment group （MaR1）. After successful modeling and drug intervention， the gastrocnemius muscle tissue of 5 mice （n = 5） from each group was collected for transcriptome sequencing and bioinformatics analysis. The remaining samples were utilized to assess histopathological damage and to detect the expression of TLR4/NF-κB p65 and NLRP3/GSDMD proteins. The MDA content and CAT activity in the serum were determined using kits. In vitro， L6 skeletal muscle cells were stimulated with LPS and ATP to establish a pyroptosis model. After modeling， ELISA was applied to measure the content of IL-1β and IL-18 in the supernatant of each group. Results Bulk RNA sequencing analysis demonstrated that， in comparison with the control group， the TLR4/NF-κB/NLRP3 signaling pathway and the expression of pyroptosis-related genes were significantly up-regulated in the LL-IRI group. Moreover， the intervention of MaR1 could reverse the above-mentioned trend， as MaR1 negatively regulated the activation of inflammasomes and the biological process associated with pyroptosis. Immunohistochemistry indicated that the expression of TLR4/NF-κB p65 and NLRP3/GSDMD was significantly enhanced in the LL-IRI group （P < 0.01）， accompanied by an increase in serum MDA content （P < 0.01） and a decrease in CAT activity （P < 0.01）. MaR1 treatment could significantly improve these pathological， molecular， and biochemical parameters. The results of in vitro experiments showed that， compared with the normal group， there was a significant increase in the release of inflammatory factors IL-1β and IL-18 at the end of pyroptosis in the LPS + ATP group （P < 0.01）. After the intervention of MaR1， the release of IL-1β and IL-18 in the LPS + ATP group was significantly reduced （P < 0.01）. Conclusion MaR1 may inhibit pyroptosis by blocking the TLR4/NF-κB/NLRP3 inflammatory cascade， thereby alleviating lower limb ischemia/reperfusion （I/R） injury in mice.

Key words: Maresin1, lower limb ischemia-reperfusion injury, pyroptosis, toll-like receptor 4

中图分类号:

R654.3

吕俊,邓堂,彭锦,王迅开,吴江鹏,金桂云. Maresin1通过TLR4/NF-κB/NLRP3通路抑制焦亡减轻下肢缺血再灌注损伤的机制[J]. 实用医学杂志, 2026, 42(10): 1849-1857.

Jun LÜ,Tang DENG,Jin PENG,Xunkai WANG,Jiangpeng WU,Guiyun JIN. Mechanism of maresin1 in alleviating lower limb ischemia-reperfusion injury by inhibiting pyroptosis via the TLR4/NF-κB/NLRP3 pathway[J]. The Journal of Practical Medicine, 2026, 42(10): 1849-1857.

图/表 7

图1

图2

图3

图4

图5

图6

图7

参考文献 27

[1]	CARMON L， PETERS A A， LABAN N， et al. Part I： Acute lower limb ischemia-reperfusion injury： Pathophysiology and experimental interventions［J］. Vasc Endovascular Surg， 2026， 60（3）： 255-270. doi：10.1177/15385744251387771 . doi: 10.1177/15385744251387771
[2]	刘洋，何春水，张丽峰，等. 机械性血栓清除术治疗急性下肢动脉缺血中应用AngioJet的疗效及预后［J］. 实用医学杂志， 2022， 38（10）： 1255-1259. doi：10.3969/j.issn.1006-5725.2022.10.016 . doi: 10.3969/j.issn.1006-5725.2022.10.016
[3]	DENG T， PENG J， YE B， et al. Near-infrared fluorogenic probe enables real-time imaging of HOCl to reveal MAR1-mediated suppression of pyroptosis in limb ischemia-reperfusion injury［J］. Anal Chem， 2025， 97（48）： 26599-26606. doi：10.1021/acs.analchem.5c04923 . doi: 10.1021/acs.analchem.5c04923
[4]	ZHANG M， GUO B， ZHANG X， et al. IFP35， a novel DAMP， aggravates neuroinflammation following acute ischemic stroke via TLR4/NF-κB/NLRP3 signaling［J］. J Neuroinflammation， 2025， 22（1）： 164. doi：10.1186/s12974-025-03492-6 . doi: 10.1186/s12974-025-03492-6
[5]	GOUCHOE D A， ZHANG Z， KIM J L， et al. Improving lung allograft function in the early post-operative period through the inhibition of pyroptosis［J］. Med Rev， 2024， 4（5）： 384-394. doi：10.1515/mr-2023-0066 . doi: 10.1515/mr-2023-0066
[6]	周文洋，廖烨晖，田明昊，等. NLRP3炎性小体在脊髓损伤后小胶质细胞中的作用［J］. 中国组织工程研究， 2025， 29（13）： 2849-2860. doi：10.12307/2025.035 . doi: 10.12307/2025.035
[7]	宋行行，刘鑫源，李虹霖，等. 细胞焦亡在脑缺血再灌注损伤中作用机制的研究进展［J］. 生命科学， 2025， 37（3）： 296-303. doi：10.13376/j.cbls/2025030 . doi: 10.13376/j.cbls/2025030
[8]	AL-KHARASHI L， ATTIA H， ALSAFFI A， et al. Pentoxifylline and thiamine ameliorate rhabdomyolysis-induced acute kidney injury in rats via suppressing TLR4/NF-κB and NLRP-3/caspase-1/gasdermin mediated-pyroptosis［J］. Toxicol Appl Pharmacol， 2023， 461： 116387. doi：10.1016/j.taap.2023.116387 . doi: 10.1016/j.taap.2023.116387
[9]	武禹佳，武文印，李艳，等. 隐丹参酮调节TLR4/NF-κB/NLRP3信号通路对高糖诱导的心肌细胞焦亡的影响［J］. 中西医结合心脑血管病杂志， 2024， 22（14）： 2553-2558. doi：10.12102/j.issn.1672-1349.2024.14.010 . doi: 10.12102/j.issn.1672-1349.2024.14.010
[10]	谷岩，何菊，侯骊坤，等. 急性下肢缺血再灌注损伤机制的研究进展［J］. 齐齐哈尔医学院学报， 2020， 41（12）： 1521-1522. doi：10.3969/j.issn.1002-1256.2020.12.025 . doi: 10.3969/j.issn.1002-1256.2020.12.025
[11]	SAITO-SASAKI N， SAWADA Y， NAKAMURA M. Maresin-1 and inflammatory disease［J］. Int J Mol Sci， 2022， 23（3）： 1367. doi：10.3390/ijms23031367 . doi: 10.3390/ijms23031367
[12]	WU H， WANG Y， FU H， et al. Maresin1 ameliorates sepsis-induced microglial neuritis induced through blocking TLR4-NF-κ B-NLRP3 signaling pathway［J］. J Pers Med， 2023， 13（3）： 534. doi：10.3390/jpm13030534 . doi: 10.3390/jpm13030534
[13]	ZHANG Q， WANG L， WANG S， et al. Signaling pathways and targeted therapy for myocardial infarction［J］. Signal Transduct Target Ther， 2022， 7（1）： 78. doi：10.1038/s41392-022-00925-z . doi: 10.1038/s41392-022-00925-z
[14]	刘慧玲，吴传新，龙贤梨，等. LPS与ATP共同诱导小鼠原代腹腔巨噬细胞焦亡模型的建立［J］. 中国免疫学杂志， 2023， 39（10）： 2028-2033. doi：10.3969/j.issn.1000-484X.2023.10.003 . doi: 10.3969/j.issn.1000-484X.2023.10.003
[15]	BROUWERS K， VAN GEEL S R W M， VAN MIDDEN D， et al. Added value of histological evaluation of muscle biopsies in porcine vascularized composite allografts［J］. J Clin Med， 2024， 13（17）： 5167. doi：10.3390/jcm13175167 . doi: 10.3390/jcm13175167
[16]	WANG H， SHI M J， HU Z Q， et al. Effect of miR-206 on lower limb ischemia-reperfusion injury in rat and its mechanism［J］. Sci Rep， 2023， 13（1）： 21574. doi：10.1038/s41598-023-48858-z . doi: 10.1038/s41598-023-48858-z
[17]	PENG J， DENG T， WANG X， et al. Advances in the treatment of lower-extremity ischemia-reperfusion injury［J］. Front Pharmacol， 2025， 16： 1576091. doi：10.3389/fphar.2025.1576091 . doi: 10.3389/fphar.2025.1576091
[18]	LORNE E， DUPONT H， ABRAHAM E. Toll-like receptors 2 and 4： Initiators of non-septic inflammation in critical care medicine？［J］. Intensive Care Med， 2010， 36（11）： 1826-1835. doi：10.1007/s00134-010-1983-5 . doi: 10.1007/s00134-010-1983-5
[19]	施佳君，杨钦钦，富丹婷，等. 冠心宁片抑制NLRP3/ASC/Caspase-1通路改善阿霉素诱导的扩张型心肌病大鼠心肌细胞焦亡［J］. 中国实验动物学报， 2024， 32（3）： 337-346. doi：10.3969/j.issn.1005-4847.2024.03.007 . doi: 10.3969/j.issn.1005-4847.2024.03.007
[20]	SHEN S， WANG Z， SUN H， et al. Role of NLRP3 inflammasome in myocardial ischemia-reperfusion injury and ventricular remodeling［J］. Med Sci Monit， 2022， 28： e934255. doi：10.12659/MSM.934255 . doi: 10.12659/MSM.934255
[21]	DE OLIVEIRA T H C， GONÇALVES G K N. Liver ischemia reperfusion injury： Mechanisms， cellular pathways， and therapeutic approaches［J］. Int Immunopharmacol， 2025， 150： 114299. doi：10.1016/j.intimp.2025.114299 . doi: 10.1016/j.intimp.2025.114299
[22]	SHIH Y V， TAO H， GILPIN A， et al. Specialized pro-resolving mediator Maresin 1 attenuates pain in a mouse model of osteoarthritis［J］. Osteoarthritis Cartilage， 2025， 33（3）： 341-350. doi：10.1016/j.joca.2024.10.018 . doi: 10.1016/j.joca.2024.10.018
[23]	CHEN Y， WU X， LI J， et al. The mechanisms of specialized pro-resolving mediators in pain relief： Neuro-immune and neuroglial regulations［J］. Front Immunol， 2025， 16： 1634724. doi：10.3389/fimmu.2025.1634724 . doi: 10.3389/fimmu.2025.1634724
[24]	XIAO H， LIU J， CAI Q， et al. Maresin 1 alleviates myocardial ischemia-reperfusion injury in rats by suppressing inflammation［J］. Eur J Histochem， 2025， 69（4）： 4254. doi：10.4081/ejh.2025.4254 . doi: 10.4081/ejh.2025.4254
[25]	史秀丽，陈嘉琪，朱璠，等. miR-143-3p靶向调控TLR2/NF-κB/NLRP3通路对溃疡性结肠炎细胞焦亡的影响［J］. 实用医学杂志， 2024， 40（15）： 2056-2062. doi：10.3969/j.issn.1006-5725.2024.15.003 . doi: 10.3969/j.issn.1006-5725.2024.15.003
[26]	CAI Q， ZHAO C， XU Y， et al. Qingda granule alleviates cerebral ischemia/reperfusion injury by inhibiting TLR4/NF-κB/NLRP3 signaling in microglia［J］. J Ethnopharmacol， 2024， 324： 117712. doi：10.1016/j.jep.2024.117712 . doi: 10.1016/j.jep.2024.117712
[27]	CHANG S Y， LI Y T， ZHU H Y， et al. Buyang Huanwu Decoction stabilizes atherosclerotic vulnerable plaques by regulating intestinal flora， TLR4-NF-κB-NLRP3 inflammatory pathway and mitophagy［J］. Phytomedicine， 2025， 142： 156751. doi：10.1016/j.phymed.2025.156751 . doi: 10.1016/j.phymed.2025.156751